Longevity & AgingGLP-1 Drug Enters Phase 2 Trial to Slow Progressive Multiple Sclerosis
A GLP-1 receptor agonist called pegsebrenatide has entered a Phase 2 trial for progressive multiple sclerosis, a condition where nerve cells steadily deteriorate even when inflammation seems controlled. Developed by Neuraly, the drug was specifically designed to target neurodegeneration rather than just metabolic symptoms. GLP-1 receptors exist in the brain, and researchers believe activating them may reduce neuroinflammation — the same chronic inflammatory process linked to Parkinson's, Alzheimer's, and even general aging. Earlier trials in Parkinson's patients showed the drug slowed motor decline, especially in those under 60. This trial signals a broader scientific shift: GLP-1 therapies may eventually become tools for preserving brain health and function across aging, not just managing weight or blood sugar.
